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Abstract
Background: A sizeable number of HIV-infected patients receiving HAART do not maintain
prolonged virologic suppression. We evaluated long-term HIV viral load (VL) responses to HAART
as a risk factor for AIDS events (AE) that is independent of CD4 responses.
Methods:  A cohort of patients with pre-therapy CD4 < 200/mm3 who had CD4 and VL
measurements for > one year after receiving HAART at a university clinic were prospectively
enrolled. Cox proportional multivariate regression model was used to determine whether CD4
and VL responses were independently associated with new AE.
Results: The patient (N = 214) mean baseline CD4 = 92/mm3, VL = 219,000 c/mL and follow-up
duration 42.3 months (range 13–72 months). A new AE occurred in 56 patients; CD4 cell count
response to HAART that remained < 200/mm3 throughout the study period was a significant risk
factor for new AE (RR = 9.7–12.5; p < 0.001). Similarly, VL responses that remained > 5,000 c/mL
during this period was also a significant risk factor (RR = 6.7–12.8; p = 0.001) that was independent
of CD4 response adjusted for <> 200/mm3.
Conclusion: Maintaining adequate long-term virologic responses to HAART provides a clinical
benefit independent of CD4 responses.
Background
Despite an overall decline in AIDS-associated illnesses
since the introduction of HAART [1,2], some patients
receiving combination antiretrovirals remain at risk for
developing new AIDS events (AE) [3,4]. Those who have
a pre-treatment CD4 cell count < 200/mm3 [5-9] or have
insufficient CD4 cell responses to HAART [6] are at risk for
progressing to AIDS or dying while receiving therapy. Per-
sistent viremia [10], independent of insufficient CD4 cell
count responses [13-16], has also been shown to be a pre-
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dictor of disease progression. These studies, however,
have differed in regards to the VL that they identify as
being predictive of disease progression-- > 1,000 c/mL
[10], > 7,000 c/mL [13], or > 20,000 c/mL [11]. Further-
more, although these studies have linked short virologic
markers in response to HAART with a successful clinical
outcome [11-14], the importance of sustaining immuno-
logic and virologic responses to HAART over a more pro-
longed time period remains to be addressed.
It is important to evaluate whether maintaining adequate
responses to long-term HAART treatment has clinical sig-
nificance for several reasons. First, evaluating whether
long-term virologic response is an independent predictor
of new AE has relevance for the sizeable number of
patients receiving HAART who do not maintain pro-
longed virologic suppression [1-4,15]. Also, the meaning
of persistent viremia is especially pertinent to those who
have high-level resistance to antivirals, but nonetheless
sustain an immunologic benefit while continuing their
failing HIV regimen [16]. Furthermore, evaluating
whether immunologic responses to HIV treatment is an
independent risk factor for disease progression is applica-
ble to those patients who are unable to mount significant
CD4 cell elevations, regardless of whether they have unde-
tectable VL [17]. Thus, our aim was to determine whether
long term virologic, as well as immunologic responses to
HAART are important and independent predictors of
developing a new AE as well as to identify a level of per-
sistent viremia that is predictive of disease progression.
We chose patients with significant immune depletion
because they are at highest risk for disease progression
[3,5].
Methods
We identified HIV-infected patients treated at the Univer-
sity of Michigan HIV/AIDS Treatment Clinic (UMHATC)
who had a baseline CD4 cell count < 200 cells/mm3
before initiating a HAART regimen. The study began on
January 31, 1996; patients were enrolled into this pro-
spective cohort from the time therapy was initiated if they
received at least twelve months of HIV therapy and were
followed to January 1, 2005. The definition of HAART for
this study was guided by DHHS guidelines [18]. Patients
were included if they were antiviral naïve before starting
HAART or if they had previously received one or two nucl-
eoside agents. Patient information was extracted from an
electronic database (Solutions™ Patient Management Sys-
tem). The research was carried out according to the princi-
ples of the Declaration of Helsinki and the study was
approved by the Institutional Review Board of the Univer-
sity of Michigan Health System.
Data on markers of response to HAART (i.e., CD4 and VL
levels that were obtained during the course of routine
UMHATC practice on an every three month basis), as well
as occurrence of a new AE (1993 CDC AIDS Surveillance
definition) [19], were extracted from the electronic data-
base system. CD4 cell counts were determined using flow
cytometry, and HIV RNA levels were performed using a
reverse transcriptase polymerase chain reaction assay
(Amplicor; Roche Diagnostics, Branchburg, New Jersey,
USA). For purposes of consistency, a VL value of < 400
copies/mL was considered undetectable for the study
period, as lower limit changed to < 50 c/mL in 1999 in the
middle of our study period. We also recorded assessment
of adherence that was entered into our electronic database
by nurses, social workers, and physicians, as was our
standardized practice during this study period.
To compare baseline characteristics between patients who
developed an AE and those who did not, we used histo-
grams to examine distributions of variables that were col-
lected. Appropriate transformations were applied on
variables found asymmetric in the following analysis.
Baseline quantitative characteristics of patients (e.g. age,
CD4, VL) were described using mean and standard devia-
tion, and qualitative characteristics (e.g. gender, presence
of AE at baseline) using proportion. A t test was used to
compare quantitative characteristics between patients
who developed an AE and those who did not. A Chi-
square test was used to compare qualitative characteristics
between groups.
To determine probabilities of occurrence of a new AE
from HAART initiation, we measured time to first AE and
used Kaplan-Meier curves. To determine averaged VL
trends after initiating HAART we used lowess smooth
curves fitted to all patients, as well as to those who devel-
oped an AE and those who did not. We then determined
VL values for the entire study period, as well as for four
specified periods: 1–12 months, 13–24 months, 25–36
months and 37–48 months after initiating HAART.
To determine risk factors for developing a new AE, we
used a Cox proportional hazard multivariate regression
model. The proportional hazard assumption was then
examined by plotting the complementary log-log trans-
formation of the survival functions separately within sub-
groups. Pre-treatment factors that were examined as
predictors for a new AE included demographic factors
(e.g. age and gender), prior NRTI use, and presence of AE
at baseline. For a given VL measurement at a particular
time point after initiation of HAART, persons were consid-
ered at risk for newly diagnosed AE for 1–6 months after
the time the measurement was made. For each time
period, we classified VL responses to HAART (adjusted for
a CD4 response of <> 200 cells/mm3) into separate cate-
gories to determine whether a particular VL category was
independently associated with presence of a new AE. TheJournal of Translational Medicine 2005, 3:40 http://www.translational-medicine.com/content/3/1/40
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relative risks of new AE for patients in specified VL catego-
ries were based on the fitted proportional hazard model
and 95% confidence intervals were estimated. All statisti-
cal tests were two-sided, and a p-value less than 0.05 was
considered statistically significant. Statistical software R
1.7.0 was used for all statistical analysis.
Results
Patient Population and AE Description
Two hundred and fourteen patients (21% of 1,014
patients treated at UMHATC during the study period)
were included in the analysis. Table 1 gives the demo-
graphic and clinical features of the population, including
prior nucleoside use and presence of AE at baseline prior
to initiating HAART. The mean duration of follow up for
the entire population after starting HAART was 42.3 ±
37.4 (range 13–82 months), and a total of 9,288 person-
months was included in the analysis. The incidence rate of
a first new AE was 6.1/100 person years for the entire pop-
ulation. There was no significant difference in presence of
baseline AE (P = 0.14), or prior nucleoside agent use (P =
0.54) between those who developed an AE and those who
did not (P = 0.28). Similarly, there was no significant dif-
ference in adherence between the two groups; 48 of the 56
patients who developed a new AE were noted to be adher-
ent with their prescribed HAART regimen on a regular
basis (86%) as opposed to 143 of the 158 patients who
did not (91%). Table 1 shows that patients without an AE
had a more brisk mean CD4 increase, more substantial VL
decline, and a greater percentage of undetectable VL than
those who did develop an AE.
Fifty-six of the 214 patients (26%) developed a new AE;
the mean time from HAART initiation to AE was 26.5 ±
21.2 (range 1 – 84 months). Four patients, all of whom
had experienced a new AE, died during the study period.
Figure 1 shows that the probability of a patient remaining
free of a new AE after 12 and 48 months of HAART was
96.1% (95% CI, 93.5,98.8), and 78% (95% CI, 71.9,86),
respectively. There were 60 episodes of new AE that
occurred in 56 patients (two patients had 2 new AE and
one had 3), as well as AE that were present pre-treatment.
Disseminated Mycobacterium avium complex (MAC) infec-
tion (13 patients), Pneumocystis jiraveci pneumonia (PcP,
8), Kaposi's sarcoma (6), candida esophagitis and non
Hodgkin's lymphoma (5 each) were the most common
AEs. Three of these AEs represented a recurrence of an AE
that was present at baseline prior to initiating HAART: PcP
(1 patient), MAC (1) and CE (1). 77% of patients in
whom MAC was diagnosed were receiving prophylaxis
with a macrolide agent, and 88% of those with PcP were
receiving pneumocystis prophylaxis. Others included
mycobacterial and cryptococcal infections (4 patients
each), progressive multifocal leukoencephalopathy and
cryptosporidiosis (3 each), HIV encephalopathy and
recurrent bacterial infections (2 each), and chronic Herpes
simplex infections and histoplasmosis (1 each).
On Treatment CD4 and VL Responses and Association 
with a New AIDS Event
Figure 2 plots the averaged CD4 responses to HAART
throughout the entire study period for all patients, and
according to whether a new AE occurred. Figure 2 shows
Table 1: Demographic, Clinical Features, Mean CD4* and Viral Load** According to Whether an AE Occurred.
Laboratory Value Patients with AE (n = 56) Patients without AE (n = 158)
Demographic
Age ± SD (range) 37.9 ± 8.28 (16 – 65.4) 39.4 ± 8.79 (15.2 – 67.8)
HIV risk (no.) MSM 27 MSM 82
HTS 7 HTS 34
IVDU 4 IVDU 12
Other 22 Other 36
Clinical
OI (no.) at Baseline (%) 7 (12%) 25 (15%)
Prior NRTI (no.) 12 (21%) 27 (17%)
Baseline Laboratory Values
CD4 62 107
VL 257,136 196,832
Follow Up Laboratory Values
CD4 (Change from Baseline) 109 (47) 369 (262)
VL (Change from Baseline) 159,517 (-97,619) 29,743 (167, 089)
Number (%) with Undetectable VL at any 
point during follow up
46 (82%) 142 (89%)
Number (%) with Undetectable VL 12 (23%) 95 (62%)
*CD4 in cells/mm3
**VL in c/mL
Abbreviations: HTS (Heterosexual), NRTI (Nucleoside Reverse Transcriptase Inhibitor).Journal of Translational Medicine 2005, 3:40 http://www.translational-medicine.com/content/3/1/40
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that the CD4 response for patients in whom a new AE
developed was much lower throughout the entire time
period than for those in whom an AE did not occur.
Throughout the study period, the averaged HAART-
restored CD4 cell count failed to elevate > 200 cells/mm3
in a significantly higher proportion of patients with a new
AE, 85% (48/56 patients), than those without an AE, 8%
(13/158 patients) (p < 0.001). Table 2 shows that a CD4
cell count response to HAART that remained < 200/mm3
was a significant risk factor for developing new AE for
each 12 month interval after initiating HAART (RR = 9.7–
12.5; p < 0.001).
Figure 3 plots the averaged VL responses to HAART
throughout the entire study period for all patients, and
according to whether a new AE developed. Figure 3 shows
that the virologic reduction for patients in whom a new
AE developed was much lower throughout the entire time
period than for those in whom an AE did not occur.
Throughout the study period, the averaged HAART-
restored VL remained > 5,000 c/mL in a significantly
higher proportion of patients with a new AE; 55% (31/56
patients), than those without an AE; 24% (37/158
patients) (p = 0.02). In a multivariate analysis adjusting
for CD4 counts of 200 cells/mm3, a VL response > 5,000
c/mL was a significant risk factor for developing a first new
AE for each 12 month interval after initiating HAART (RR
= 6.7–12.8; p = 0.001) (Table 2). Similarly, a VL response
that remained > 50,000 c/mL was also a significant risk
factor for developing new AE for each 12 month interval
after initiating HAART (RR = 3.7–12.6; p = 0.007) (Table
2). However, VL responses that remained > 1,000 c/mL
approached but did not reach statistical significance for
developing a first new AE (RR 2.34–4.41; p = 0.05–0.14)
for each individual 12 month interval after initiating ther-
apy (Table 2).
Discussion
The present study demonstrates that failure to maintain
low levels of viremia is a significant risk factor for HIV dis-
ease progression that is independent of CD4 responses.
Our results are consistent with studies showing the clini-
cal importance of achieving a VL response at 6–12 months
that is independent of CD4 responses [10-14], and stress
the benefit of maintaining a durable VL response through-
out a 48 month period. The VL level identified as carrying
an increased risk for an AIDS event in our study, > 5,000
c/mL, is within the range that some reports identify as
independently predictive of disease progression, i.e., >
1,000 c/mL [10], > 7,000 c/mL [13], but lower than
another report (20,000 c/mL) [11]. Regardless of the pre-
cise value, a reduction in VL that cannot be maintained at
low or undetectable levels, a predictor of new AIDS events
CD4 Response to HIV Therapy for Entire Population and  Patients with or without AE Figure 2
CD4 Response to HIV Therapy for Entire Population and 
Patients with or without AE. The averaged CD4 responses 
to HAART throughout the entire study period were deter-
mined by lowess smooth curves fitted to all patients for all 
patients, as well as for those in whom a new AE occurred or 
did not occur. At each time point during the study, the CD4 
response for patients in whom a new AE developed was 
much lower than for those in whom an AE did not occur.
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Kaplan-Meier curve of First AE for the entire population Figure 1
Kaplan-Meier curve of First AE for the entire population. The 
percentage of patients without an AE is plotted according to 
time (months) after HAART initiation. The probability of a 
patient remaining free of a new AE after 48 months of 
HAART was 78% (95% CI, 71.9, 86).
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in our study, is not uncommon for patients receiving
HAART [20]. It is unlikely that the difference in VL
response between the groups in our study can be attrib-
uted to different adherence rates between the two groups.
However, because adherence measurement tools were not
used as part of routine clinical care, we could not calculate
the percentage of each patient's adherence over a long-
term basis and then compare this variable between
groups.
In fact, several published studies suggest that virologic
failure rates are especially high, varying from 20% to 70%,
in those who are either treatment-experienced or have low
baseline pre-treatment CD4 cell counts and high VL val-
ues [21-23]. In one study, for example, lower CD4 counts
and higher VL at baseline predicted virologic failure, but
there was no clear cut-off value at which the risk started to
increase [24]. In another study, baseline CD4 count < 25
cells/mm3 was associated with a significantly higher risk
of virologic failure, as was a baseline VL ≥ 100,000 copies/
mL [25].
Identifying that long-term virologic response is an inde-
pendent predictor of new AE has relevance for the sizeable
number of patients receiving HAART who cannot main-
tain prolonged virologic suppression [20]. Also, the
meaning of persistent viremia is pertinent to those who
have high-level resistance to antivirals, but nonetheless
sustain an immunologic benefit while continuing their
failing HIV regimen [26]. At present, the outcome and
optimal management of these patients remains undefined
[27]. Switching to an optimized regimen may not be an
available option, since the durability of a salvage regimen
selected for patients with high level resistance to many
antivirals may be brief. Consequently, some physicians
continue a failing regimen despite persistent viremia for
patients who maintain an immune benefit until other
active treatment options become available. By identifying
VL as a risk factor for disease progression that is independ-
Viral Load Response to HIV Therapy for Entire Population  and Patients with or without AE Figure 3
Viral Load Response to HIV Therapy for Entire Population 
and Patients with or without AE. The averaged VL responses 
to HAART throughout the entire study period were deter-
mined by lowess smooth curves fitted to all patients for all 
patients, as well as for those in whom a new AE occurred or 
did not occur. At each time point during the study, the VL 
reduction for patients in whom a new AE developed was 
much lower throughout the entire time period than for 
those in whom an AE did not occur.
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Table 2: Risk of Developing New AIDS Event according to CD4 and VL Response Categories.
CD4 Response Time After HAART Relative Risk and CI P Value
Absolute CD4 < 200 (1–12 months) RR = 4.45 (95% CI: 1.8, 10.9); p < 0.001
(13–24 months) RR = 3.95 (95% CI: 1.62, 9.63); p = 0.002
(25–36 months) RR = 5.19 (95% CI: 1.99, 13.5); p = 0.001
(37–48 months) RR = 3.21 (95% CI: 1.61, 10.8); p = 0.02
VL Response
Absolute VL > 1,000 (1–12 mos) RR = 2.34 (95% CI: 0.87, 6.26); p = 0.09
(13–24 mos) RR = 2.77 (95% CI: 0.81, 9.48); p = 0.10
(25–36 mos) RR = 4.41 (95% CI: 0.99, 19.7); p = 0.052
(37–48 mos) RR = 2.74 (95% CI: 0.71, 9.1); p = 0.14
Absolute VL > 5,000 (1–12 mos) RR = 4.66 (95% CI: 2.02, 10.7); p = 0.001
(13–24 mos) RR = 3.24 (95% CI: 1.06, 9.88); p = 0.03
(25–36 mos) RR = 6.41 (95% CI: 1.8, 22.8); p = 0.004
(37–48 mos) RR = 4.23 (95% CI: 1.05, 6.0); p = 0.05
Absolute VL > 50,000 (1–12 mos) RR = 3.77 (95% CI: 1.68, 8.43); p = 0.001
(13–24 mos) RR = 2.78 (95% CI: 1.04, 7.39); p = 0.021
(25–36 mos) RR = 2.89 (95% CI: 1.80, 5.51); p = 0.04Journal of Translational Medicine 2005, 3:40 http://www.translational-medicine.com/content/3/1/40
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ent of CD4 response, our study suggests that discordant
responders may be at risk for disease progression while
being maintained on a virologically failing regimen.
It is not rare for patients, such as those followed in the
present study, to first receive HAART after they develop an
AIDS event or their CD4 cell count falls below 200/mm3.
In one report, "late testers" – those whose diagnosis of
HIV occurred within 12 months of their AIDS diagnosis,
accounted for 39% of persons diagnosed with AIDS in San
Francisco between 2001 and 2002 [28]. Also, in a New
York study, 27% of persons with newly diagnosed HIV
infection were concurrently diagnosed with AIDS [29].
Furthermore, in clinical practice, some patients, despite
having been tested earlier, may not have received HAART
until a later stage because they may not have wished to
take HIV therapy until becoming symptomatic. These rea-
sons, along with sole availability of mono or dual nucleo-
side agents prior to 1996, accounted for why 21% of
patients followed in our practice did not receive HAART
until their CD4 count fell below 200/mm3 and therefore
met criteria for our study.
Our finding that PCP and MAC remain the most frequent
AE in the HAART era is consistent with prior studies [30].
Similarly, our finding that chemoprophylaxis failure
among those with the most advanced immunosuppres-
sion was the most significant source of new PCP cases is
also consistent with a HOPS cohort study [31], along with
studies showing that KS and NHL remain the major AIDS-
associated malignancies in the HAART era [32-34]. In con-
trast, our study showed that CMV and cerebral toxoplas-
mosis occur less often than in the Pre-HAART era. One
possible explanation for this observation is that memory
CD4 cells, expanded by HAART, may recognize antigens
on previously acquired pathogens that persist in a latent
state, thereby preventing clinical reactivation. This possi-
bility, if confirmed, suggests that there may be benefits of
receiving HAART that are independent of immunologic
and virologic responses currently used to monitor ther-
apy.
Conclusion
In summary, our study emphasizes the clinical benefit of
maintaining virologic responses as well as immunologic
throughout long-term HAART treatment. Incomplete
responses to HAART are not uncommon in clinical prac-
tice, and identifying them as risk factors for disease pro-
gression emphasizes several treatment options that are
available. For example, changing regimens in patients
who have persistent virologic replication who have other
antiviral options, as recommended by treatment guide-
lines [35], is supported by identifying VL as an independ-
ent predictor of disease progression. Nevertheless, for
those with no option other than to remain on their cur-
rent regimen for prolonged periods of time because of
high level drug resistant HIV, clinical progression may
eventually occur, even in those who have a CD4 benefit
despite persistent viremia. Our findings stress the impor-
tance of developing new potent antiretroviral agents in
order to sustain the overall decline in AIDS-associated ill-
nesses that has been witnessed since the introduction of
HAART.
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